SEARCH

SEARCH BY CITATION

References

  • 1
    Fiedorek S, Tolia V, Gold BD, et al. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2005; 40: 31927.
  • 2
    Gunasekaran TS, Hassall EG. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993; 123: 14854.
  • 3
    Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr 2000; 137: 8007.
  • 4
    Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book L. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35(Suppl. 4): S30818.
  • 5
    Boccia G, Manguso F, Miele E, Buonavolont`a R, Staiano A. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable? Am J Gastroenterol 2007; 192: 12917.
    Direct Link:
  • 6
    Hassall E (for the International Pediatric Omeprazole Study Group). Omeprazole for maintenance therapy of erosive esophagitis in children. Gastroenterology 2000; 118: A658.
  • 7
    Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007; 150: 2627.
  • 8
    Kuipers EJ. Proton pump inhibitors and gastric neoplasia. Gut 2006; 55: 121721.
  • 9
    Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41: 185200.
  • 10
    Solcia E, Fiocca R, Villani L, Luinetti O, Capella C. Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogenesis. Am J Surg Pathol 1995; 19(Suppl. 1): S17.
  • 11
    Jensen RT. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006; 98: 419.
  • 12
    Haga Y, Nakatsura T, Shibata Y, et al. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Dig Dis Sci 1998; 43: 2537.
  • 13
    Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 6619.
  • 14
    Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 135670.
  • 15
    Havu N, Maaroos HI, Sipponen P. Argyrophil cell hyperplasia associated with chronic corpus gastritis in gastric ulcer disease. Scand J Gastroenterol Suppl 1991; 186: 904.
  • 16
    Hassall E, Dimmick JE, Israel DM. Parietal cell hyperplasia in children receiving omeprazole. Gastroenterology 1995; 108: A110.
  • 17
    Israel DM, Dimmick JE, Hassall E. Gastric polyps in children on omeprazole. Gastroenterology 1995; 108: A110.
  • 18
    Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 116181.
  • 19
    Rindi G, Solcia E. Endocrine hyperplasia and dysplasia in the pathogenesis of gastrointestinal and pancreatic endocrine tumors. Gastroenterol Clin North Am 2007; 36: 85165, vi.
  • 20
    Rindi G. Clinicopathologic aspects of gastric neuroendocrine tumors. Am J Surg Pathol 1995; 19(Suppl. 1): S209.
  • 21
    Carmack SW, Genta RM, Schuler CM, Saboorian MH. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am J Gastroenterol 2009; 104: 152432.
  • 22
    Abou-Saif A, Gibril F, Ojeaburu JV, et al. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer 2003; 98: 24961.
  • 23
    Sanduleanu S, De Bruine A, Stridsberg M, et al. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 2001; 31: 80211.